ºñÁê¾ó
Publications

Research Papers

°Ô½ÃÆÇ º¸±â
ÀÛ¼ºÀÚ ÀÛ¼ºÀÚ°ü¸®ÀÚ
³¯Â¥ 2023-07-12 11:33:22
Á¦¸ñ Comparison of clinical features and 1-year outcomes between patients with psychotic disorder not otherwise specified and those with schizophrenia.
±â»ç ¸µÅ© http://onlinelibrary.wiley.com/doi/epdf/10.1111/eip.13276
Comparison_of_clinical_features_and_1-year_outcomes_between_patients_with_psychotic_disorder_not_otherwise_specified_and_those_with_schizophrenia..JPG

Abstract

Aim: Research on psychotic disorder not otherwise specified (PNOS) that clearly mentions its subgroups is very rare. This study was conducted to identify the demographic and clinical features, cognitive function, and 1-year outcomes of patients with early stage PNOS compared with those with early stage schizophrenia (SZ).

Methods: The study subjects were 54 and 321 patients with PNOS and SZ, respectively, who were registered at least more than 1 year ago. Due to drop out, only 37 and 210 patients with PNOS and SZ were evaluated at the 1-year follow-up. We compared clinical variables (duration of untreated psychosis, symptom severity, self-rating scales, and so on), cognitive function, and short-term outcomes (treatment response, remission, compliance, drop out, relapse) between the two groups.

Results: The patients with PNOS were associated with higher diagnostic stability (53.7%) compared with those in previous studies. They had lower symptom severity, better treatment response at 2 months and higher remission rates at 12 months, but poorer compliance at 6 months compared with patients with SZ. Level of cognitive impairment in PNOS was intermediate between those of SZ patients and healthy controls.

Conclusions: These findings indicate that PNOS has unique clinical features, suggesting that it should be treated as a distinct clinical syndrome. At the same time, however, prevention of its possible progression to other psychotic disorders in some patients with PNOS is also important.

Keywords: clinical staging; diagnostic stability; outcome; psychotic disorder NOS.

÷ºÎÆÄÀÏ


ÃÑ °Ô½Ã¹° 54 ÆäÀÌÁö 1/4

   
°Ô½ÃÆÇ ¸®½ºÆ®
¹øÈ£ Á¦¸ñ ÆÄÀÏ ÀÛ¼ºÀÚ ³¯Â¥ Á¶È¸¼ö
54 Associations between post-traumatic stress diso... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.09.21 192
53 Different topological patterns in structural co... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.09.18 195
52 Medications for Psychosis: Dopamine Blockers an... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.09.15 120
51 Validation of the Korean Version of the Communi... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.28 112
50 Predictors of full recovery in patients with ea... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.28 207
49 Development of the Korea-Polyenvironmental Risk... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.12 53
48 The factor structure and clinical utility of cl... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.12 51
47 Three-year outcomes and predictors for full rec... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.12 36
46 Associations of Clozapine Use With Psychosocial... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.12 114
45 DNA Methylation Profiles of the DRD2 and NR3C1 ... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.12 35
ÇöÀç±Û Comparison of clinical features and 1-year outc... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.12 36
43 Clozapine Optimization: A Delphi Consensus Guid... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.07.12 80
42 An automatic analysis framework for FDOPA PET n... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2023.04.18 193
41 Modeling Approach with Therapeutic Drug Monitor... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2022.09.14 220
40 The Relationship Between Frontostriatal Connect... ÷ºÎÆÄÀÏ  °ü¸®ÀÚ 2022.07.25 225